Skip to main content
SpringerLink
Log in

Beyond current aprepitant evidence: room for improvement on dose selection and chemotherapy-induced nausea and vomiting risk factors

  • Letter to the Editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Smith AR, Repka TL, Weigel BJ (2005) Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 45:857–860

    Article  PubMed  Google Scholar 

  2. Bodge M, Shillingburg A, Paul S et al (2014) Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study. Pediatr Blood Cancer 61:1111–1113

    Article  CAS  PubMed  Google Scholar 

  3. Gore L, Chawla S, Petrilli A et al (2009) Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52:242–247

    Article  PubMed  Google Scholar 

  4. Kang HJ, Loftus S, Taylor A et al (2015) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol 16:385–394

    Article  CAS  PubMed  Google Scholar 

  5. Bakhshi S, Batra A, Biswas B, et al (2015) Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer

  6. Molassiotis A, Aapro M, Dicato M et al (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manag 47:839–848

    Article  Google Scholar 

  7. Vanbockstael J, Coquan E, Gouerant S, et al. (2015) How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study. Support Care Cancer

  8. Dupuis LL, Boodhan S, Holdsworth M, et al. (2012) Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatric Oncology Group of Ontario; Toronto. http://www.pogo.ca/_media/File/guidelines/POGO_Acute_AINV_Guideline_Quick_Summary_Feb_21_2013.pdf. Accessed 22 September 2015

  9. Emend® capsules prescribing information. Merck & Co., Inc (2014) www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf. Accessed 22 September 2015

  10. A study to evaluate aprepitant for the prevention of post operative nausea and vomiting in children (MK-0869-219). https://clinicaltrials.gov/ct2/show/NCT01732458. Accessed 22 September 2015

Download references

Acknowledgments

The author was given a monthly scholarship from the Brazilian Ministry of Education.

Author information

Authors and Affiliations

  1. Clinical Pharmacy Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

    Lucas Miyake Okumura

Authors
  1. Lucas Miyake Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucas Miyake Okumura.

Ethics declarations

Conflict of interests

The author declares that he has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okumura, L.M. Beyond current aprepitant evidence: room for improvement on dose selection and chemotherapy-induced nausea and vomiting risk factors. Support Care Cancer 24, 1009–1010 (2016). https://doi.org/10.1007/s00520-015-3046-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-015-3046-5

Keywords

Search

Navigation